Psychological health and immunotherapy for TNBC
Part of Cancer, Mental health, Skin clinical trials.
This study looks at how psychological factors and the immune system affect treatment response in women with triple-negative breast cancer. Researchers will use questionnaires and biological samples to understand these links.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with triple-negative breast cancer (TNBC).
- You are planning to receive immunotherapy as part of your first treatment before surgery.
- You are willing to fill out questionnaires and follow up with the study team.
- You do not have cancer that has spread to distant parts of your body.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This study looks at how your immune system responds to triple-negative breast cancer. It will test your blood or tissue to learn more about your body's natural defenses against the cancer.
This study looks at how immunotherapy combined with chemotherapy affects ovary function in younger women with early-stage triple-negative breast cancer. It aims to understand if this treatment impacts fertility, which can help patients make informed decisions.
This trial looks at whether adding immunotherapy to chemotherapy before surgery helps people with triple-negative breast cancer. It compares different treatment approaches to see which works better.
This study looks at the bacteria found in the tumor to see if they affect how well chemotherapy or immunotherapy works in treating triple-negative breast cancer. The goal is to find ways to predict treatment response and improve care.
This trial tests whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer who have already completed 6 cycles of first-line treatment. It aims to see if a longer break between doses can be just as effective with fewer hospital visits.
Hear when a new General Anxiety Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.